Drug intelligence / Profile preview

[11C]PBR28

Development stage
Unknown
Lead developer
National Institute of Mental Health
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

[11C]PBR28 is a carbon-11 radiolabeled small molecule PET radioligand developed by the National Institute of Mental Health (NIMH). It specifically targets the 18-kDa translocator protein (TSPO), formerly known as the peripheral benzodiazepine receptor (PBR). TSPO is expressed at low levels in the healthy central nervous system but is significantly upregulated in activated microglia and astrocytes during neuroinflammation. [11C]PBR28 was designed as a high-affinity alternative to the first-generation tracer [11C]PK11195, offering improved signal-to-noise ratios and superior specific binding. It is used as a diagnostic imaging tool in clinical research to quantify neuroinflammation across various conditions, including Alzheimer's disease, multiple sclerosis, Parkinson's disease, and traumatic brain injury.

Other names
N-acetyl-N-(2-[11C]methoxybenzyl)-2-phenoxy-5-pyridinamine[(11)C] PBR28
02

Targets

TSPO (Translocator Protein (18 kDa))

Beyond the preview

Go deeper on [11C]PBR28.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [11C]PBR28.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call